The peptides presented by MHC molecules on SCLC cells and their recognition by T cells have not been explored so far. H.-G. Rammensee and C. Gouttefangeas will decipher the MHC-class I and -class II ligandome of SCLC, identify immunogenic SCLC neo- and non-mutated T cell antigens, and characterize tumor-specific T cells in SCLC patients. In particular, personalized vaccination approaches based on patients´ tumor ligandome analysis should address the future design of SCLC immune therapies.
Professor (C4), Chair of the Department of Immunology
University of Tübingen
Institute of Cell Biology, Department of Immunology
Group Leader
University of Tübingen
Interfaculty Institute for Cell Biology
Department of Immunology